[DEMO] SARCOMA CONNECT update from ASCO 2022
[DEMO] SARCOMA CONNECT update from ASCO 2022
SARCOMA update by Dr. Jonathan Trent, University of Miami Hospital, USA
SARCOMA update by Dr. Jonathan Trent, University of Miami Hospital, USA
Prof. Jonathan Trent
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla eget arcu eu metus pellentesque auctor. Phasellus vel vestibulum tortor. Phasellus vitae est mi.
Prof. Jonathan Trent
Medical Oncology
University of Miami Health System
United States (US)
| 
min
|
May 2022
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Dr Trent discusses two Sarcoma presentaitons presented at ASCO 2022
- Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemecur-voyagerotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). Martin McCabe, PhD, University of Manchester
- Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST). First Author: Cesar Serrano PhD, MD, © Vall d'Hebron Institute of Oncology (VHIO)
SARCOMA CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Karyopharm Therapeutics.
Other programmes of interest
28 min
Other programmes developed by Prof. Jonathan Trent
Prof. Jonathan Trent
Medical Oncology
University of Miami Health System
United States (US)
